Paid Clinical Trials Murfreesboro

Discover 1,226 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,226

A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting

Sponsor:

Amgen

Location:

Nashville TN, Jackson TN, New Albany IN, Lexington KYshow 30 more

Code:

NCT06072482

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Avacopan

Placebo

Standard of Care

Study of ALXN2220 Versus Placebo in Adults With ATTR-CMStudy of ALXN2220 Versus Placebo in Adults With ATTR-CM

Recruiting

PHASE3

Sponsor:

Alexion Pharmaceuticals, Inc.

Location:

Nashville TN, Atlanta GA, Memphis TN, Greenville SCshow 44 more

Code:

NCT06183931

Conditions

Transthyretin Amyloid Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALXN2220

Placebo

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington DiseaseImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Recruiting

PHASE2

PHASE3

Sponsor:

Vanderbilt University Medical Center

Location:

Nashville TN

Code:

NCT04713982

Conditions

Huntington Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Deutetrabenazine

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer PatientsGastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients

Recruiting

Sponsor:

Vanderbilt University Medical Center

Location:

Nashville TN

Code:

NCT00899626

Conditions

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Pancreatic Cancer

Precancerous Condition

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting

PHASE1

PHASE2

Sponsor:

Aulos Bioscience, Inc.

Location:

Nashville TN, Huntersville NC, Grand Rapids MI, Houston TXshow 2 more

Code:

NCT05267626

Conditions

Advanced Solid Tumor

Metastatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AU-007

Aldesleukin

Avelumab

Trial of Indication-Based Transfusion of Red Blood Cells in ECMOTrial of Indication-Based Transfusion of Red Blood Cells in ECMO

Recruiting

Sponsor:

Boston Children's Hospital

Location:

Nashville TN, Atlanta GA, Cincinnati OH, Indianapolis INshow 17 more

Code:

NCT05405426

Conditions

Extracorporeal Membrane Oxygenation

Red Blood Cell Transfusion

Organ Failure, Multiple

Eligibility Criteria

Sex: All

Age: 0 - 6

Healthy Volunteers: Not accepted

Interventions

Red blood cell transfusion

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisA Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting

PHASE3

Sponsor:

Bristol-Myers Squibb

Location:

Nashville TN, Jasper AL, Birmingham AL, Louisville KYshow 87 more

Code:

NCT06003426

Conditions

Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

BMS-986278

BMS-986278 Placebo

The PREDICT Registry:The PREDICT Registry:

Recruiting

Sponsor:

PreludeDx

Location:

Nashville TN, Columbus OH, Akron OH, Cleveland OHshow 11 more

Code:

NCT03448926

Conditions

DCIS

Eligibility Criteria

Sex: Female

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Treatment Recommendation Surveys

7-gene biosignature

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Location:

Nashville TN, Birmingham AL, Saint Matthews KY, Atlanta GAshow 34 more

Code:

NCT06297226

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Arlocabtagene Autoleucel (BMS-986393)

A Study of EP0031 in Patients With Advanced RET-altered MalignanciesA Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting

PHASE1

PHASE2

Sponsor:

Ellipses Pharma

Location:

Nashville TN, Lexington KY, Chicago IL, Evanston ILshow 12 more

Code:

NCT05443126

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EP0031